key: cord-0773048-cpgnxbpj
authors: Grupper, Ayelet; Katchman, Helena
title: SARS-CoV-2 Vaccines: Safety and Immunogenicity in Solid Organ Transplant Recipients and Strategies for Improving Vaccine Responses
date: 2022-01-22
journal: Curr Transplant Rep
DOI: 10.1007/s40472-022-00359-0
sha: c1e25915b77a6f6129cfa9f2f7c30ebbd432fc75
doc_id: 773048
cord_uid: cpgnxbpj

PURPOSE OF REVIEW: While solid organ transplant (SOT) recipients are at the highest risk for severe complications and increased mortality from COVID19 disease, their vaccination against SARS-CoV-2 remains challenging due to fear of immune-mediated adverse events and suboptimal immune response. Our current review is aimed to summarize current knowledge about the safety and efficacy of SARS-CoV-2 vaccines, describe factors that are correlated with immune response, and discuss strategies to improve vaccine immunogenicity in SOT recipients. RECENT FINDINGS: SARS-CoV-2 vaccines are safe in SOT recipients and not related to rejection or other major adverse events. The immune response to two doses of vaccine is suboptimal and correlated to age and magnitude of immunosuppression. Administration of a third vaccine dose brings to significant amplification of immune response. SUMMARY: This review strengthens the existing recommendation of vaccination by three doses of vaccine in all SOT recipients and completion of vaccination before transplantation if possible.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting disease, coronavirus disease 2019 (COVID- 19) , have affected millions of persons worldwide. COVID-19 in solid organ transplant (SOT) recipients is associated with increased morbidity and mortality due to comorbidities and immunosuppression state [1] [2] [3] [4] .

Nair et al. [5] showed a 30% increased risk of ventilation or death due to COVID-19 in SOT recipients compared with matched controls, and although symptoms of COVID-19 disease are generally similar to those in non-transplant patients [6, 7] , rates of COVID-19-related hospitalizations in SOT recipients are higher than the general population [6] [7] [8] .

In addition, immunocompromised patients who do not mount a strong immune response against SARS-CoV-2 are likely to shed the virus for a longer time and be a source of continued unintended exposure to others [9] [10] [11] , as well as a potential source of new variants [9] .

Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach for controlling the pandemic and are being vigorously pursued. Based on data from other vaccinations, the immune response of solid organ recipients to vaccination may be blunted [12] [13] [14] , and an adequate vaccine response cannot be assumed.

All transplant recipients are eligible for vaccination unless contraindicated from other reasons. Although the immunogenicity and efficacy of COVID-19 vaccines are uncertain in solid organ transplant recipients [15] , the potential for benefit from vaccination likely outweighs this uncertainty.

In this review, we aimed to expand the knowledge and understanding and present an overview of the safety and immunogenicity of the SARS-CoV-2 vaccine in solid organ transplant recipients.

Although there are clear evidence of immune activation caused by SARS-CoV-2, based on large observational cohort studies of transplant patients with COVID- 19, there has not yet been detected any correlation of SARS-CoV-2 infection with subsequent rejection [15] . Vaccines could induce alloimmunity by triggering an immune response that is cross-reactive with the allograft, by stimulating previously alloreactive immune cells, or through the nonspecific stimulatory effects of adjuvants that could lead to de novo alloimmunity.

While there is a theoretical concern that vaccination may trigger organ rejection [16] [17] [18] [19] , or production of de novo anti-donor-specific antibody (DSA) [19] [20] [21] , also reported for SARS-CoV-2 vaccine [22, 23] , numerous studies of some common vaccines have shown no casual association between the two [24] [25] [26] [27] [28] [29] .

Similar to that, mRNA SARS-Co-2 vaccines in SOT recipients were not significantly related to rejection events in most studies (Table 1) .

In one study [30] , the authors quote a sixfold higher incidence of rejection in third-dose versus second-dose recipients, based on only one case of rejection per group and the putative mechanism is unclear.

Taking into consideration high SARS-CoV-2 vaccine effectiveness and severe clinical spectrum of COVID-19 disease, these rare cases of rejection did not provide any basis to withholding vaccination in SOT recipients.

In immunocompetent individuals, mRNA SARS-CoV-2 vaccines, similar to other common vaccines, are noted to cause mild-to-moderate side effects, including local pain, headaches, and fatigue [31] , with the only rare occurrence of major adverse events [32, 33] . Among transplant recipients, SARs-CoV-2 vaccines were not associated with any unexpected short-term local and systemic side effects (Table 1) .

Data regarding immune response to SARS-CoV-2 vaccines have been exponentially accumulating over the last several months.

Some of the recent publications on this topic are summarized in Table 1 .

These accumulating data consistently demonstrate a suboptimal humoral immune response among transplant recipients following two doses of mRNA SARS-CoV-2. Among kidney and lungs transplant recipients, the majority of patients did not develop an appreciable humoral immune response (seropositivity rates are between 8.2 to 66% and 10 to 47.4% for kidney and lung transplant recipients, respectively), while liver and heart recipients had a better response (seropositivity rates between 37.5 to 80% and 18.2 to 62% for liver and heart transplant recipients, respectively) ( Table 1 ).

In addition, impairments in T-cell response were also described, with a high rate but reduced magnitude of spikespecific T helper cell response, as well as limited effector cytokine production in SOT recipients [34 •, 35, 36•, 37••] , and diminished generation of plasmablasts and memory B cells in response to mRNA vaccine [38] . Although cellular immunity may offset the absence of post-vaccination neutralizing antibodies in SOTRs, among 148 kidney transplant recipients, 35% developed neither humoral nor cellular responses following vaccination [39•] .

The clinical importance of this laboratory finding is supported by growing evidence, suggesting that elapsed time after the vaccination has a major role in breakthrough infections due to wanning immunity and declining of antibody titers [40] . Bergwerk et al. [41] described breakthrough infections with SARS-CoV-2 in a cohort of healthcare workers and a correlation of these infections with the declining of neutralizing antibody titers in the peri-infection period.

Growing bulk of evidence confirm that this observation is true also for immunocompromised patients. Wadei et al. [42] reported on seven SOTRs with undetectable or low titer anti-spike antibodies who developed COVID-19 infection after receiving one or two doses of the SARS-CoV-2 mRNA vaccine. The clinical presentation and course of these patients were comparable to those of SOT recipients who had COVID-19 infection and have not been vaccinated. 

Observation of the waning immunity demonstrated by decreased antibody levels after two doses of vaccine in the general population [41] as well as breakthrough infections among vaccinated SOT recipients, including severe COVID19 cases [43 ••, [44] [45] [46] [47] [48] [49] , together with a suggested correlation between breakthrough infections and the time that has passed since the second vaccine dose, has led experts including the FDA to recommend the administration The CDC recommends that patients who are moderately to severely immunocompromised (including SOT recipients) should receive an additional dose of mRNA COVID-19 vaccine at least 28 days after the second dose [53] . Several countries have made similar recommendations [54] [55] [56] [57] .

First reports on the administration of a third dose of the mRNA vaccine to SOT recipients have been shown to improve the immune response without causing any shortterm, serious adverse events ( Table 2 ). The third dose of the vaccine in SOT transplant recipients was effectively resulted in increased IgG anti-S levels, including in transplant recipients who were seronegative after two doses.

Hall et al. [58] studied 120 solid organ transplant recipients who had received two doses of an mRNA vaccine and were randomly assigned to either the third dose of mRNA vaccine or saline placebo. A serologic response was present in 55% of patients in the vaccine group compared with 18% in the placebo group.

Kamar et al. [59 ••] reported on SOT recipients (kidney, liver, lung, heart, pancreas) who received three doses of BNT162b2; the prevalence of anti-SARS-CoV-2 antibodies was 0%, 4%, and 40% before the first, second, and third doses, respectively, and 68% 4 weeks after the third dose. Unfortunately, approximately 50 to 70% of SOTRs who were seronegative after two doses remained seronegative. Adverse effects were similar to those reported after prior doses ( Table 2) .

Longitudinal follow-up and evaluation of the clinical implication of the third dose in this population are needed to more completely characterize the impact of additional vaccine doses.

The ideal timing of vaccination in the post-transplantation setting is not known. In all cases, the likelihood of contracting COVID-19 (based on community prevalence) against the optimal timing with the highest probability of developing a protective immune response to vaccination should be weighted.

ISHLT recommendations are to delay vaccination for at least one month from the time of transplantation and for at least three months after use of T-cell-depleting agents (e.g., anti-thymocyte globulin) or specific B cell-depletion agents (e.g., rituximab) [60] .

According to NIH recommendation [61] , transplant surgery should be delayed until ≥ 2 weeks after COVID-19 vaccination. If delayed surgery is not possible, it may be advisable to delay vaccination of transplant recipients for several weeks to months after surgery and the associated use of highly immunosuppressive medications.

The American Society of Transplantation (AST) also recommends vaccinating at least two weeks before transplantation but does not specify whether vaccination should be delayed when T or B cell-depleting agents are used [62] .

Our group [63••] has demonstrated a significantly higher rate (90%) of positive humoral response to BNT162b2 SARS-CoV-2 vaccine in kidney transplant recipients vaccinated before transplantation, as compared to individuals vaccinated after transplantation (45%), with appreciable anti-spike antibody response sustained in pre-transplant vaccinated patients even after induction immunosuppression and high-dose steroids treatment. Mean antibody levels in seropositive recipients were similar to healthy controls, suggesting a better chance of responding to the vaccine when administered pre-transplantation.

Age Advanced age was found to be associated with low antibody response in immunocompetent patients after COVID-19 disease [64] , as well as after mRNA SARS CoV-2 vaccination [65] . Older age was a consistent variable related to a poor immune response in recent studies (Table 1), demonstrating that even in immunosuppressed patients, age is an independent predictor of poor immunological response.

The seroresponse to vaccination is related to the net burden of immunosuppression: The greater the degree of immunosuppression, the less likely the patient will respond to immunization. These findings are not only clinically obvious but also supported by previous studies that found a strong correlation of poor seroprotection [21] and increased infection rates [66] with increasing intensity of immunosuppression regimen.

The influence of different immunosuppressive regimens on vaccination response was studied in previous years. A number of studies evaluated response rates to influenza and pneumococcal vaccination in patients receiving glucocorticoids. While the immune response was preserved, although mildly reduced, in most patients on a chronic low dose of glucocorticoids [67] [68] [69] , the response was inadequate in patients on high dose [70] .

Additional studies demonstrated a dose-related correlation of MMF to decreased influenza and cholera vaccine responsiveness in renal transplant subjects [71] [72] [73] .

Several studies on SOT recipients in mRNA SARS CoV-2 vaccination demonstrate concordant results with significant 

One possible approach to overcome the low response rate in SOTRs is to choose optimal timing for vaccination, with accumulating evidence of the advantage of pre-transplant vaccination of transplant candidates. After the transplantation, the decision of optimal vaccination timing is more challenging and should take into consideration epidemiological data of the danger of SARs-Cov-2 contraction versus pursuit to delay vaccination at least 1 to 3 months after transplantation considering a decreased immune response to the vaccine during this period (Table 1) .

While multiple studies are concordant in the conclusions about the negative influence of immunosuppression (especially MMF and high-dose glucocorticoids) on the vaccination success, there are insufficient data to guide modifications of immunosuppression in anticipation of, or preparation for, vaccination, and society guidelines do not recommend routine modification of immunosuppression [75] .

The introduction of a third (booster) dose is currently the best way to increase the immune response to the SARs-Cov-2 vaccine, and we have sufficient evidence to recommend it in SOT recipients. The longevity of this immune response should be evaluated and may guide us in the decision about the need for additional boosters in the future.

Promising results from the very recent study that used switching to a different vaccine platform in non-responders (e.g., viral vector-based vaccination after failure to achieve a response after mRNA vaccination) propose an additional useful strategy [76] .

Accumulating data about SARA-CoV-2 vaccination in SOT recipients repeatedly confirm the high safety profile of mRNA vaccines. Reduced immunogenicity of the vaccine in SOT recipients is correlated mainly with high immunosuppression burden (and proximity to transplant surgery) and older age. While additional long-term studies are needed to evaluate the possible strategies to increase vaccine-induced protection in SOT recipients, this review strengthens the existing recommendation of vaccination by three doses of 

Ethics Approval and Consent to Participate This article does not contain any studies with human or animal subjects performed by any of the authors.

The authors declare no competing interests.

Papers of particular interest, published recently, have been highlighted as:

• Of importance •• Of major importance

Is COVID-19 infection more severe in kidney transplant recipients?

An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants

COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium

COVID-19 infection in kidney transplant recipients at the epicenter of pandemics

An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients

COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature

COVID-19 clinical manifestations and treatment strategies among solid-organ recipients: a systematic review of cases

COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients

Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited

Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer

Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer

Serologic vaccination response after solid organ transplantation: a systematic review

Immune responsiveness and protective immunity after transplantation

Solid organ transplantation and response to vaccination

Immune responses to SARS-CoV-2 in solid organ transplant recipients

Update on immunizations in solid organ transplant recipients: what clinicians need to know

Safety of influenza vaccine in heart transplant recipients

Influenza virus vaccination and kidney graft rejection: causality or coincidence

De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients

Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients

Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients

Positive flow cytometry crossmatch with discrepant antibody testing results following COVID-19 vaccination

SARS-COV-2 vaccination with BNT162B2 in renal transplant patients: risk factors for impaired response and immunological implications

Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation -a systematic review of randomized trials, observational studies and case reports

Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients

Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis

Outcomes associated with influenza vaccination in the first year after kidney transplantation

Influenza vaccination is efficacious and safe in renal transplant recipients

Adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccines and solid organ transplant rejection: systematic signal evaluation and lessons learnt

Antibodies, boosters, and optimizing SARS-CoV-2 vaccines for transplantation: a call for more research

First month of COVID-19 vaccine safety monitoring -United States

SARS-CoV-2 Vaccines: much accomplished, much to learn

Considerations in boosting COVID-19 vaccine immune responses

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) primeboost vaccination in kidney transplant recipients

Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients

Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients

Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients

Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel

Covid-19 Breakthrough infections in vaccinated health care workers

COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination

Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients

Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients

Clinically Significant COVID-19 following SARS-CoV-2 vaccination in kidney transplant recipients

Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients

COVID-19 after two doses of mRNA vaccines in kidney transplant recipients

Breakthrough COVID-19 infections after mRNA vaccination in solid organ transplant recipients in Miami

Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients

Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus. Fact sheet for healthcare providers administering vaccine

CDC COVID-19 vaccines for moderately to severely immunocompromised people

A country-by-country guide to coronavirus vaccine booster plans

ECDC and EMA highlight considerations for additional and booster doses of COVID-19 vaccines

Health Canada vaccination recommendation in special populations

Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

Transplantation ISfHaL: SARS-CoV-2 Vaccination in heart and lung transplantation. Recommendations from the ISHLT COVID-19 Task Force

Special considerations in solid organ transplant, hematopoietic stem cell transplant, and cellular therapy candidates, donors, and recipients

American Society of Transplantation COVID-19 Vaccination Guidance

Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccine

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed

A comparison of triple-therapy with double-therapy immunosuppression in cadaveric renal transplantation

Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids

Influenza vaccination in patients with rheumatic diseases. Safety and efficacy JAMA

Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome

Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist

Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients

Comparison of the immunogenicity of Dukoral® oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate -a controlled trial

Response of transplant recipients to influenza vaccination based on type of immunosuppression: a meta-analysis

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

2021% 2005% 2018% 20COV ID19% 20VAC CINE% 20FAQS-final% 20upd ate. pdf (Accessed on

Review of early immune response to SARS-CoV-2 vaccination among patients with CKD

Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Ramathibodi Transplant infectious diseases Rtid study group T. SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 Study)

Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring

Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: the debate is open!

SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients

Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients -a prospective cohort study

Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants

A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response

Poor antibody response after two doses of SARS-CoV-2 vaccine in transplant recipients

BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response

Imperial Renal COVID-19 vaccine study group in collaboration with the OCTAVE Study Consortium. Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Humoral Response to SARS-Cov-2 vaccination in liver transplant recipients -a single-center experience. Vaccines (Basel)

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine

Antibody response to severe acute respiratory syndrome-coronavirus-2 messenger RNA vaccines in liver transplant recipients

Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses

Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients

A report of the response to the third dose of SARS-CoV-2 vaccine in SOTR

Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

Cellular and humoral immune responses after three doses of BNT162b2 mRNA SARS-Cov-2 vaccine in kidney transplant

Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series

A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings

Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study